BIIB080

← Pipeline

BIIB080

Biogen / Ionis · Alzheimer's disease
Mid-stage active active, not recruiting CT.gov grounded

Tau-lowering antisense program that matters because the field needs credible non-amyloid shots on goal.

Open Alzheimer's disease hub Filter main pipeline

Program overview

Mechanism
tau antisense oligonucleotide
Modality
ASO
Phase
Mid-stage
Status
active
Recruitment
active, not recruiting
Confidence
medium
Watch priority
2
Last verified
20 Apr 2026

Sponsor and trial identifiers

Sponsor
Biogen / Ionis
Trial IDs
NCT05399888
ClinicalTrials.gov exact matches: NCT05399888

Regions and recruitment

Active in 17 regions
United States Australia Belgium Canada Czechia Denmark Finland France Germany Italy Japan Netherlands Poland Spain Sweden Switzerland United Kingdom

Indication tags

Alzheimer's tau

Milestones and catalysts

Last milestone
Tau-targeted approaches remain one of the most important non-amyloid categories to track.
Next expected catalyst
Updated biomarker and dose-expansion signals.

Related pages

Disease hub Alzheimer's disease hub Disease-specific views with programs, mechanisms, and related context.
Research Research agenda Research notes and background around Alzheimer's disease.
Key Targets Key targets The mechanisms and intervention levers behind these programs.
Discover Discover Explainers and visual introductions to the science behind neurodegeneration.
Join Get involved Contribute research, writing, design, engineering, or review.

Related programs

Each card explains why it is here so you can read the overlap at a glance.

Priority 1
Approved / Late-stage active active, not recruiting

Late-stage anti-amyloid program with high strategic importance for the Alzheimer's treatment landscape.

Shown because it shares same disease bench and shared biology: alzheimer's with BIIB080.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Further rollout, label evolution, and follow-up data.
Last verified
20 Apr 2026

Lecanemab

Eisai / Biogen · Alzheimer's disease
Priority 1
Approved / Late-stage active active, not recruiting

Anti-amyloid antibody program targeting plaque clearance in early Alzheimer's disease.

Shown because it shares same disease bench and shared biology: alzheimer's with BIIB080.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Additional post-approval data and uptake signals.
Last verified
20 Apr 2026
Priority 2
Mid-stage active active, not recruiting

A serious tau program that matters because the Alzheimer's field still needs credible combination therapy attempts.

Shown because it shares same disease bench and shared biology: alzheimer's, tau with BIIB080.
Mechanism
anti-MTBR tau antibody
Modality
monoclonal antibody
Next catalyst
Whether the tau-plus-amyloid combination thesis produces a clearer signal than monotherapy tracks.
Last verified
20 Apr 2026
Priority 2
Late-stage active active, not recruiting

A precision-style Alzheimer's program built around APOE4 biology rather than a broad undifferentiated patient pool.

Shown because it shares same disease bench and shared biology: alzheimer's with BIIB080.
Mechanism
anti-amyloid oligomer modulation
Modality
small molecule
Next catalyst
Long-term extension updates and any signal on APOE4-enriched positioning.
Last verified
20 Apr 2026

Source links

ClinicalTrials.gov NCT05399888 ClinicalTrials.gov search Biogen pipeline
Scroll to Top